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Abstract
Background: Appropriate choice and use of prognostic models in clinical practice require the use of good
methods for both model development, and for developing prognostic indices and risk groups from the models. In
order to assess reliability and generalizability for use, models need to have been validated and measures of model
performance reported. We reviewed published articles to assess the methods and reporting used to develop and
evaluate performance of prognostic indices and risk groups from prognostic models.
Methods: We developed a systematic search string and identified articles from PubMed. Forty-seven articles were
included that satisfied the following inclusion criteria: published in 2005; aiming to predict patient outcome;
presenting new prognostic models in cancer with outcome time to an event and including a combination of at
least two separate variables; and analysing data using multivariable analysis suitable for time to event data.
Results: In 47 studies, Cox models were used in 94% (44), but the coefficients or hazard ratios for the variables in
the final model were reported in only 72% (34). The reproducibility of the derived model was assessed in only 11%
(5) of the articles. A prognostic index was developed from the model in 81% (38) of the articles, but researchers
derived the prognostic index from the final prognostic model in only 34% (13) of the studies; different coefficients
or variables from those in the final model were used in 50% (19) of models and the methods used were unclear in
16% (6) of the articles. Methods used to derive prognostic groups were also poor, with researchers not reporting
the methods used in 39% (14 of 36) of the studies and data derived methods likely to bias estimates of differences
between risk groups being used in 28% (10) of the studies. Validation of their models was reported in only 34%
(16) of the studies. In 15 studies validation used data from the same population and in five studies from a different
population. Including reports of validation with external data from publications up to four years following model
development, external validation was attempted for only 21% (10) of models. Insufficient information was provided
on the performance of models in terms of discrimination and calibration.
Conclusions: Many published prognostic models have been developed using poor methods and many with poor
reporting, both of which compromise the reliability and clinical relevance of models, prognostic indices and risk
groups derived from them.
Background
Prognosis is central to medicine, often being used to
direct diagnostic pathways and to inform patient treat-
ment [1,2]. Most clinicians use patient and disease char-
acteristics to predict patient outcome. For accurate
outcome prediction, multiple risk factors need to be
considered jointly because single factors have insuffi-
cient predictive value to distinguish patients who are
likely to do well from those likely to do poorly.
Prognostic models allow multiple risk factors to be used
systematically, reproducibly and using evidence based
methods [2-5]. Prognostic models are also referred to as
clinical prediction models, clinical prediction rules, risk
scores and nomograms. Although a large number of
prognostic models are published, very few models are
used in clinical practice [3].
To understand whether a particular prognostic model
or prognostic index provides a useful tool to inform
patient treatment, the accuracy of the model predictions
need to be reported, both in terms of how well the model
separates individuals who develop the outcome from
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dicted risks are to the actual observed risks (calibration).
Currently several measures of model performance are
used, although there is no consensus on which are the
most clinically useful given the range of different clinical
decisions directed from prognostic models [6].
This article examines how prognostic models are used
to develop clinical predictions about cancer patients,
and the measures of model performance that are used.
We assessed, by a systematic review, the methods used
in 47 articles on prognostic models where the specific
research aim was to develop a new prognostic model as
a combination of at least two separate variables to pre-
dict patient outcome. We focussed on the reporting and
use of methods used to developp r o g n o s t i ci n d i c e sa n d
risk groups from the models and measures used to
determine how well the model predicted prognosis. We
have set our findings in the context of the methodologi-
cal literature that has studied the impact of using differ-
ent methods of model predictions.
D e v e l o p m e n to fg o o dp r o g n o s t i cm o d e l sn e e d s
researchers to provide reliable information for patient
treatment decisions, including measures of the reliability
and generalizability of this information.
Methods
Details of the literature search, inclusion criteria and
methods in data extraction are reported in the compa-
nion paper (Mallett et al [7]). To identify articles, pub-
lished subsequent to the original articles on model
development, that might include external validations of
the 47 prognostic models, we completed a citation
search on each of the 47 original articles (30 December
2009). We used the Web of Science® citation search
(citation databases: Science Citation Index expanded,
Social Sciences Citation Index, Arts & Humanities Cita-
tion Index and Conference Proceedings Citation Index -
Science 1990 onwards) through the ISI Web of Knowl-
edge
SM (Thomson Reuters 2009). Titles and abstracts
for the cited references were screened and where appro-
priate full articles (SM).
Validity assessment and data extraction
Topics covered included: number of patients and events,
source of patients, endpoints for analysis, methods and
reporting of multivariate analysis, numerical and graphi-
cal presentation of model, creation of prognostic index
and risk groups, model discrimination and calibration,
methods of validation and usability of reported model.
In a companion paper (Mallett et al [7]) we report the
assessment of methods and reporting, including study
design, sample size, number of patients and events, out-
come definition, number and coding of variables in
model, methods of selection of variables.
Twenty items were extracted by duplicate data extrac-
tion by two of three reviewers (SM, SD, RW) with refer-
ence to a third reader where necessary. One reviewer
(SM) assessed all articles and all items. For eight items
examination of disagreements led to refinement of data
items and re-assessment by a single reviewer (SM) due
to study resource and timeline limitations. If more than
one model was presented in the article, the first
reported in the title, abstract or text was selected.
Results
We assessed 47 articles in which prognostic models of
cancer were developed for methods and reporting of the
prognostic model performance [8-54]. A detailed
description of the characteristics of these studies is
reported in an accompanying paper (Mallett et al [7]).
Across 20 data extraction items relating to reporting of
model performance measures, there was agreement in
76% of the items between readers. Over half of the differ-
ences were caused by ambiguities in the articles, the defi-
nition of the data item or where the disagreement
required reference to a third reader to resolve. Examples
of items frequently referred to a third reader included
which methods used to create risk groups should be clas-
sified as data driven; and how much information from
the final model was used to derive the prognostic index.
Reporting of model
Cox models were used in 94% (44) of studies (Table 1)
of which three articles included an additional modelling
method (two on recursive partitioning analysis, one on
artificial neural networks) [10,36,48]. Of the three arti-
cles where a Cox model was not used, a Weibull model
Table 1 Numerical and graphical presentation of model
(n = 47)
% (n)
articles
Statistical model used
Cox only 88 (41)
Cox plus other (two RPA, one ANN) 6 (3)
Other (one Weibull, one RPA, one unclear) 6 (3)
Assumption of proportional hazards tested† 21 (10)
Final prognostic model reported* 96 (45)
Regression coefficient reported** 72 (34)
Reproducibility of model development assessed†† 11 (5)
Model with same variables, not same coefficients 9 (4)
Model generating both new variables and
coefficients
4 (2)
† In three articles assumption of proportional hazards was not applicable as
models used were RPA (recursive partitioning analysis) and ANN (artificial
neural network).
* Two articles did not report the final model
** Not applicable in two articles using RPA or ANN model
†† One article used both methods to examine model reproducibility.
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analysis in another [25], and in a third article Cox mod-
elling was rejected, but the method used was not
reported [12]. The assumption of proportional hazards
w a sr e p o r t e da st e s t e di n1 0o ft h eC o xm o d e l s
[8,12,21,22,29,33,35,40,45,49].
The final model used to develop the prognostic index,
score or to make prognostic statements was reported in
96% (45) of the articles (Table 1). The model coeffi-
cients (hazard ratio or log hazard ratio) were reported
in 72% (34) of the articles. In two articles numerous
models were presented but not the model used to
develop the prognostic index [50,52].
Reproducibility of model development
Evaluation of model development methods in terms of
both variable selection and coefficient estimates often
reveals very different models can be selected based on
bootstrap resampling of the patient dataset [55,56].
Where intermediate steps are used in model develop-
ment, such as testing interaction terms or collapsing
categories of variables, it might not be practicable to
validate all model building steps fully [57].
In five articles the reproducibility of model develop-
ment was examined (Table 1), in two articles research-
ers reselected the variables in the model [18,33], and in
four articles the coefficient values were refitted
[33,38,39,45]. Four of these articles also included valida-
tion of the final model in addition to evaluation of
model reproducibility [18,33,39,45].
Development of prognostic index
W h e r eap r o g n o s t i cm o d e li sb a s e do nal a r g es a m p l e
size and relevant variables are included in the final
model, reasonable estimates of the coefficient values for
each variable are likely. The prognostic index is devel-
oped as a sum of the variables from the model, weighted
by their coefficient values (log hazard ratio values). If
the model was developed from a small sample, coeffi-
cient values in the model are likely to be unreliable,
partly due to idiosyncrasies in data that the model is
developed from rather than generalizable patterns [58].
Validation of prognostic models, either internally (using
the same data) or externally (using different data), is
essential to understand the reliability of both the choice
of variables and the values of coefficients for each
variable.
The development of a prognostic index was reported
in 81% (38) of the articles (Table 2). Of the nine studies
where a prognostic index was not developed, four stu-
dies included risk groups [19,25,36,48] and in five stu-
dies a model was developed but neither prognostic
index nor risk groups were developed from the model
[10,21,22,42,54].
In the 38 articles where a prognostic index was devel-
oped, the final model was not reported in two articles
[50,52]. In nine articles the coefficients of the final
model were not reported [13,18,20,29,32,39,44,50,52].
Appropriate methods for construction of a prognostic
index from the final model were used in 34% (13 of 38)
of articles [8,14-16,23,27,33,35,38,40,43,47,51], where the
prognostic index was developed as the sum of the vari-
ables from the model, weighted by their coefficient
values (log hazard ratio) (Table 2). In six articles the
methods used to develop the prognostic index from the
final model were not reported or were unclear
[17,24,26,32,39,44].
In 21% (8 of 38) of the articles, the variables from the
final model were used to develop the prognostic index
but not the coefficient values [9,12,20,28,34,44,46,49],
although in five of these articles authors stated their
intention to use the coefficient weightings from the final
model. In these eight articles that used the same vari-
ables as the final model, the following differences to the
appropriate modelling methods were reported: counting
factors, where equal weighting is applied to each vari-
able was used in four articles [12,28,44,46]; a different
weighting of a single variable from the weighting in the
final model was assigned in one article [34]; coefficients
from the univariable analysis instead of from the multi-
variable final model were used in one article [20]; a
negative sign was missing from the coefficient in the
prognostic index in one article [49]; score weightings
that did not correspond to the order of the coefficients
from the final model were assigned in one article [9].
Table 2 Prognostic index, risk groups and model fitting
% (n) articles
Prognostic index (PI) developed 81 (38)
Components of final model used to create PI
Same variables and coefficients 34 (13/38)
Same variables but not same coefficients 21 (8/38)
Neither same variables nor coefficients 29 (11/38)
Method unclear 16 (6/38)
Risk groups are created from prognostic model 76 (36)
Method used to create risk groups
Data driven 28 (10/36)
Equal size groups created 14 (5/36)
Other non data driven method 11 (4/36)
Method unclear 8 (3/36)
Method not reported 39 (14/36)
Number of risk groups created
Two risk groups 11 (4/36)
Three risk groups 39 (14/36)
Four risk groups 31 (11/36)
Five or more groups 11 (4/36)
Several different risk groupings used 8 (3/36)
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ables nor coefficients as reported in the final model, for
development of the prognostic index. In these articles
researchers reported using the following differences to
the appropriate methods: in two articles a previously
published prognostic index was modified by addition of
a new variable and weightings assigned to factors were
derived from two different models [37,52]; between one
and three variables were added into the prognostic
index that were not included in the final model in five
articles [11,30,45,52,53]; non-significant variables were
present in the final model, but were not included in the
prognostic index in three articles [17,24,41]; researchers
described ‘adjusting for 10 non significant variables’
without including these variables in the final model in
one article [13]; a significant variable was dropped from
the final model from the prognostic index without
explanation in one article [31]; in two articles research-
ers changed how variables are coded between the final
model and prognostic index without apparently re-run-
ning the model to get new coefficients [13,31]; in four
articles researchers derived the final model by counting
variables, effectively assigning equal weighting to all fac-
tors regardless of coefficients in the model [11,13,17,30].
In four studies researchers used two of these methods
together [17,30,31,52], and in one study three of these
methods were used [13].
In 95% (36 of 38) of the studies developing a prognos-
tic index, authors reported the number of variables
used, corresponding to a median of four variables (IQR
3 to 5, range 2 to 9).
Development of risk groups
There is no consensus on how to create risk groups, or
how many risk groups to use [59]. Risk groups can be
created directly from the model or by grouping prog-
nostic index scores into risk groups. Even where there is
fair consensus on which patients would be classified as
having high risk or low risk, often for clinical purposes
physicians are most interested in reclassification of
patients at intermediate risk, for whom treatment deci-
sions are unclear [60]. A disadvantage of classifying risk
into only two groups as opposed to three or more risk
groups, is that readers of the model are unable to see
how risk changes across risk groups or to estimate risks
for alternative risk groups from those chosen by the ori-
ginal modellers.
In the absence of an ap r i o r iclinical consensus on
cutpoints for prognostic risk groups, then the currently
preferred method is to use a non data driven method to
assign risk groupings. These methods include splitting
the population into equal size groups such as thirds or
quarters. This is an equally arbitrary approach but more
efficient in terms of sample size than splitting the
prognostic index into equal intervals, which may result
in a very small number of patients in extreme risk
groups.
Data driven approaches are likely to considerably
overestimate model performance and are not advised.
Two data driven approaches are frequently used. The
minimal P-value approach leads to bias as it uses multi-
ple testing to find an optimal cut point in terms of
study results for a given data set [61,62]. The post hoc
alteration of risk group cutpoints based on study results,
such as a combination of risk groups similar on Kaplan
Meier plots, can lead to bias as hazard coefficients are
not invariant across different cutpoints of an outcome
variable [63]. Similarities can be seen in post hoc altera-
tions to the cutpoint of a diagnostic test, and how this
can bias diagnostic accuracy results [64].
Risk groups were developed from the prognostic model
or prognostic index in 76% (36) of studies (Table 2). In
nine studies researchers used non data driven methods to
develop risk groups; five used equal sized groups
[9,26,31,33,38]; two used cutpoints from previous publi-
cations [39,52]; one used arbitrary percentiles without
justification [49]; and one used categories of prognostic
index [44]. In 10 studies risk groups were created using
data driven methods that are likely to overestimate the
separation of prognostic groups when the model is vali-
dated on external datasets, in nine by combining prog-
nostic index scores or recursive partitioning model
termini with similar risk [15,17,23,25,27,30,35,36,48], in
o n eb yu s i n gam i n i m a lP-value approach [47]. The
methods used to develop risk groups were not reported
or are unclear in 17 studies.
Discrimination and calibration
The discrimination of a prognostic model indicates how
well the model separates patients who experience an
event of interest from those who do not [65,66]. Discri-
mination can be presented graphically by a Kaplan Meier
(KM) plot of survival for patients in different risk groups.
Several measures of discrimination have been devel-
oped including the R squared [3], D statistic [67],
c-index [4], SEP and PSEP [68,69], K [70], NRI [6], IDI
[6] and decision curve analysis [71]. Some of these tests
and measures can only be applied to comparisons
between categorical groups such as risk groups (for
example, log rank, NRI) whereas others can be applied
to continuous measures such as prognostic indices (ISI,
c-index, D). Some of the methods used to assess discri-
mination and calibration of a logistic regression model
cannot be applied to Cox models and vice versa [72].
The log rank test, although easy to implement along-
side a KM graph, does not give an estimate of the mag-
nitude of the separation of the risk groups but is used
to test for a difference in survival between risk groups.
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not useful measures of how well a model separates
patients with and without events [69].
The discrimination ability of a prognostic model can
be presented for the data used to develop the model
(Table 3) although these measures are more important
in understanding the performance of models in internal
and external validation (Table 4).
Table 3 summarises the presentation of discrimination
for the original dataset used to develop the model in our
sample of articles. Ninety-four percent (34 of 36) of stu-
dies that developed risk groups for a prognostic index
presented differences in survival between risk groups
using Kaplan Meier plots. The log rank test was reported
in 17 studies. The percentage survival probability at a
fixed time in the different risk groups was reported in 22
studies. In nine studies a measure of discrimination was
reported, in seven studies the c-index was used
[14,15,33,34,46,47,49] and in two studies other discrimi-
nation measures were presented [38,39] (Table 3).
Model calibration describes how well the estimates of
survival from the model correspond to the survival
from the observed data [66,73] and can be described as
a measure of the extent of bias in a model [74]. Calibra-
tion in Cox models can be presented at a specific time
point, as a plot of observed proportions of events
against predicted probabilities in a new dataset often
based on 10
ths of risk groups [75]. In logistic regression
models the Hosmer-Lemeshow test can be used, but
this as a single test does not give information on how
individual risk groups (for example, each 10
th of risk
group) is calibrated and it has limited statistical power
to assess poor calibration and is over sensitive with very
large samples. We accepted model calibration on the
model development dataset as presented if the percen-
tage survival in risk groups at a fixed time point was
shown for both the model predictions and the observed
data.
Researchers in only one study presented calibration of
the model on the model development data, at a fixed
time point, as a comparison of model predictions of per-
centage survival in risk groups with actual survival per-
centages [34]. It is unclear how censored data are
treated in the actual survival prediction data.
Table 3 Model performance on data used to develop model and usability* (n = 42)
Articles with risk groups
(n = 36)
Articles with PI but no risk groups
(n = 6**)
Presentation of discrimination of model predictions†
KM for risk groups 34 NA
Nomogram 2 4
Other graphical 2 2
% survival probability at fixed time†† 22 0
Index of discrimination (see below) 9 2
Log rank 17 NA
Unspecified P-value 6 0
No presentation 0 0
Index of discrimination$
c-index 7 1
R squared or goodness of fit or Brier score 1 1
D 00
Other - K (Begg), sensitivity and specificity 2 0
Reclassification of patient risk 0 0
Calibration
Yes 1 1
No 35 5
Model usability from article$$
Prognostic score or risk group can be assigned 33 6
Survival presented for risk group and/or prognostic score 36 5
Instructions for use suitable for physicians included 3 3
* Five articles did not develop PI or use risk groups.
**Four of six articles had some commonality: three articles included the same author, one the same department.
†More than one option possible.
†† All articles have either KM or % survival by risk group.
$ Two articles with risk groups report two indices of discrimination.
$$ Four articles are unusable, lacking one or other criteria.
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We also assessed how explicit and usable the model was
for those wanting to apply the model. For a model to be
usable by others, we required sufficient reporting to
enable a reader to compute a score or risk group, and
in addition information to link this to survival probabil-
ity. Ninety percent (38 of 42) of the studies fulfilled
both of these requirements for a usable model
(Table 3). In this assessment, the predicted survival
lines in nomograms were included as providing infor-
mation from the model on survival according to
the prognostic score. However, instructions likely to be
suitable for physicians on how to use the prognostic
model, either as specific instructions or as a
worked example, were included in only six articles
[8,9,18,32,39,45]. In two articles [18,32] example text for
the physicians to explain to patients the interpretation
of their scores was also included.
Model validation
Evaluation or validation of a prognostic model is a
process of establishing that a model works satisfacto-
rily for patients other than the original dataset used to
develop the model [69]. Model validation uses the
same model (that is, the same variables and same coef-
ficients or, equivalently, the original prognostic index)
to evaluate both discrimination and calibration of
model predictions with observed patient outcome in
new data [66].
Internal validation refers to evaluation in the same
patient data, although sometimes the term internal vali-
dation includes evaluation in different patients from the
same patient population. For internal validations on the
same patients, methods such as bootstrapping or jack-
knife methods are used. Where internal validation uses
data within the same population, methods include split
sample and cross validation [76]. In split sample
validation the data is split into a model development
and testing dataset. Cross validation is an extension of
split sampling methods, but where the sample split is
repeated so all patients have served once in the model
evaluation dataset. Although split sample and cross vali-
dation methods use different patient data to that used
to develop the model, the new data is often closely
related or a random split of the same dataset. Split sam-
ple methods and cross validation with fewer than 10
repeats, have been reported to provide an inferior vali-
dation method to bootstrapping for many reasons,
including inefficient use of data leading to less stable
model development, poor performance and bias [77].
The most stringent form of validation is external valida-
tion, where the generalizability or transportability of the
model is evaluated in new patients in a separately
collected population.
Model validation was reported in addition to model
development in 34% (16) of studies [8-10,16,18,25,
32,33,39,40,45-47,49,51,54]. In 15 studies, researchers vali-
dated using data from the same population; six used the
bootstrap method [33,39,45,46,49,51], five used a random
split [8-10,16,47], five cross validation [10,18,25,39,40],
two temporal split (Table 5). Just 11% (5) of articles
included external validation with data from a different
population setting [18,32,33,39,46].
Table 5 Reproducibility and validation of models
Topic % (n = 47)
articles
Model validation included 34 (16)
Validation dataset*
Same data (bootstrap) 13 (6)
Same population, new data** 23 (11)
External (that is, new population setting) 11 (5)
Larger series including original sample 0 (0)
Validation of models
Final model with same coefficients and
variables
26 (12)
Unclear reporting 9 (4)
Modifications suggested to model in light of
validation?
0 (0)
* Five studies included validation with more than one dataset.
** Methods used by studies were as follows: five studies used a random split,
two used temporal split, five used cross validation, one used the jacknife
method. Two studies used two and three methods respectively.
Table 4 Model performance on validation data
Articles with risk
groups
(n = 16)
Presentation of discrimination of model
predictions
KM for risk groups 1
Other graphical 0
% survival probability at fixed time 2
Index of discrimination (see below) 11
Log rank 1
Unspecified P-value 0
No presentation of discrimination 4
Index of discrimination$
c-index 10
R squared or goodness of fit 4
D0
Other - k (Begg), SEP (Graf) 2
Reclassification of patient risk 0
Calibration
Yes 2
No 14
† More than one option possible
$ Two studies reported two indices of discrimination, one study three indices
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cles (Table 5) where external validation was reported as
part of the original model development article: RCT
datasets were used in two studies [33,39], a retrospective
database was used in three studies [18,32,46], an exter-
nal validation set with some patients from an RCT and
some from a consecutive patient series were used in one
study [33]. In two studies researchers used external vali-
dations from the same hospital; one with RCT data [33],
one with different treatments [46]. Three studies used
external validation on patient data from a different hos-
pital [18,32,39].
In 13 articles the number of patients in the validation
datasets were reported (median 200, IQR 148 to 359,
range 5 to 1,782). In nine articles the number of events
in validation datasets were reported (median 110, IQR
65 to 149, range 15 to 574) [16,18,32,33,39,45,46,49,51].
Discrimination of the model in the validation dataset
was presented in 75% (12 of 16) of the articles including
validation (Table 4) [8,9,16,18,25,33,39,45-47,51]. In 11
studies one or more indices of discrimination were
reported, with the c-index reported in 10 studies and
goodness of fit P-values (AIC, BIC, Cox model fit) in
four studies.
In only four percent (2) of models had researchers pre-
sented any information on model calibration (Table 4)
[9,18]. In these studies calibration plots were reported at
a fixed time point for model predictions of percentage
survival against actual survival percentage. None of these
16 model validations resulted in any recommendations to
modify the prognostic model in the light of the valida-
tion. General rules for the need to update prognostic
models before clinical application have not yet been
established [73,78].
In addition to the five articles in our review that
included external validations, we also searched for sub-
sequent publications that included external validations
for the 47 prognostic models, using a citation search in
December 2009. For eight prognostic models [18,20,29,
34-36,46,47] subsequent articles have been published
that used external patient data and reported completion
of a model validation [79-92]. For three models, a model
evaluation was reported in one subsequent article per
model [29,35,36] whereas in five models, evaluation was
reported by more than one article [18,20,34,46,47]. The
same authors as had developed the prognostic model
had published reports of evaluation for two models
[29,36], whereas different authors reported evaluation
for six models [18,20,34,35,46,47]. Overall, in the same
or subsequent publications, 21% (10 of the 47) of mod-
els were reported as evaluated using external datasets,
although the quality of evaluations was often poor and
uninformative.
Example of good methods and reporting
Although the quality of the articles was generally disap-
pointing, we particularly wish to highlight one article
using good methods and good reporting [33]. This study
deserves mention as researchers included: reporting of
the multivariable model and its coefficients, correct use
of the multivariable to develop the prognostic index,
creation of risk groups using preferred methods, (for
example this study used equal size groups), presentation
of the model in a form usable by others, both internal
and external validation of the model. Kaplan-Meier
plots are reported for the validation data by risk groups
and a recognised discrimination measure is reported.
This same article was also the best example for our
companion article on developing prognostic models
(Mallett et al [7]) making it a good example for those
wishing to develop prognostic models to use in combi-
nation with books and articles providing good advice on
methods in prognostic modelling [3-5,69,74]
Discussion
This research has highlighted current practice in meth-
ods used to develop prognostic models for clinical pre-
dictions about the patients, and the measures of model
performance reported. The quality of prognostic models
depends on researchers understanding the assumptions
inherent in the methods and following sound principles
to ensure methods are appropriately applied [4]. Explicit
reporting of methods and performance measures of
models to other researchers is important to enable
further model validation and transparent evaluation of
clinical usefulness of models [93].
Very few articles in our study reported on how well
model predictions performed, either in terms of discri-
mination, the ability of the model to separate patients
with different outcomes, or by calibration, how accu-
rately the model estimated the probability of outcome.
Most statistical models are derived from a sequence of
data driven steps leading to likely bias both in model
development and the performance of a prognostic index
or risk groups generated from it. Although there is no
consensus on the best methods in several areas of pre-
diction modelling, such as creation of prognostic groups,
there is consensus that some methods are not advisable
[61,94]. Unfortunately this study shows that these ill
advised and biased methods are in widespread use,
which will reduce the reliability of models and predic-
tions of many prognostic models.
Though this research relates to prognostic models in
cancer, problems identified in these prognostic models
are not specific to cancer. Similar problems have been
found in reviews of other areas of medicine [95]. This
study included mostly Cox models, however the
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similar, even if some measures are different. Frequent
use of poor methods have been reported in the develop-
ment of logistic regression models [96]. A further limita-
tion of our study was that only 47 articles were
reviewed, however we judged little further value would
be obtained from review of a larger number of articles.
Reporting methods to develop risk groups
T h e r ei sl i t t l eg u i d a n c eo rc o n s e n s u so nh o wt o
develop risk groups from a prognostic index, however
using groups with equal numbers of patients or based
on a justifiable clinical reason is the preferred method.
Using data driven methods (based on outcomes of the
data analysis itself) is not advisable although we found
these methods are frequently used (in 28% of models).
Previous research has found similar inappropriate data
driven methods were frequently used [59]. Preferred
methods are those based on clinical consensus or arbi-
trary cutpoints such as quartiles of population.
In our research we found frequent use of highly biased
methods to develop models and to derive prognostic
indices and groups for prediction of patient risk. There
are no specific guidelines on how to develop, measure
performance and validate prognostic models, but there
are some excellent books and articles providing advice
on good and poor methodology [3-5,74].
Lack of reporting of model performance
Reporting of model performance using discrimination
and calibration measures was poor (Tables 3 and 4).
Only two articles reported calibration data in external
validation data (Table 4).
Previous research has also found that there is poor
reporting of model performance in terms of discrimina-
tion and calibration measures in logistic regression
models [96-98]. In prediction models in reproductive
medicine with external validation, most models reported
either discrimination or calibration [95]. Discrimination
is frequently reported using the c-index, equivalent to
t h ea r e au n d e rt h eR O Cc u r v e .T h ec - i n d e xm e a s u r e s
the probability that two patients, one with an event and
one without, will be ranked correctly. This c-index is
not related to any particular prognostic index threshold,
but is integrated across all possible thresholds, whether
clinically applicable or clinically absurd. The clinical
applicability and meaning of the c-index has been ques-
tioned recently [6]. Model goodness of fit tests are often
presented with the model development and validation,
but these tests do not indicate how well a model pre-
dicts patient outcome [72]. The newer methods that
describe model discrimination in terms of patient
reclassification between risk groups, are starting to be
used in published studies and should provide more
clinically relevant information to assess model perfor-
mance [99].
Internal and external validation
Validation of models is essential to establish whether a
prognostic model is likely to provide useful classification
of patient risk. External validation is an essential pre-
requisite before models are applied in clinical practice,
preferably by external investigators [66,76]. We found
34% of articles included some validation, but external
data from a new patient population was used in only
11% of studies. Reported external evaluation of eight
models was found in subsequent publications. In total
only 21% (10 models) were reported as externally vali-
dated in either the original articles or in the subsequent
four years. Other research has found that a large range,
0% to 52%, of articles where a prediction model was
developed, included either internal or external validation
[93,95-98].
Articles in this study did not report using multiple
imputation methods to address missing prognostic vari-
able data. Several articles confirm that only complete case
data are included in model development, indicating the
presence of selection bias in the model. Ongoing metho-
dological research provides guidelines on the use of multi-
ple imputation for missing data [100], development and
validation of models with missing data [101] and how to
apply models when missing data are present [102].
The implications for clinical medicine
Prognostic models are developed to provide objective
probability estimates to complement clinical intuition of
the physician and guidelines [73]. Many published prog-
nostic models have been developed using poor metho-
dological choices that may adversely affect model
performance. This may help to explain why so few mod-
els are used in clinical practice. Appropriate choice and
use of prognostic models in clinical practice requires
model validation and reporting appropriate measures of
model performance in order to assess reliability and
generalizability of models.
Conclusions
Development, validation and assessment of the perfor-
mance of prognostic models are complex, and depend
on researchers understanding statistical methods and
how to apply them appropriately. We found poor
reporting of the methods used to develop models and
details of the models. Questionable methods are widely
used to develop prognostic indices and few models are
validated, even using internal validation methods that do
not require additional datasets.
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